HQL.US Tekla Life Sciences Investors

Financial Services Capital Markets USA Stocks
18.95 USD
Close of Nov 15, 2026
14.72 22.04
Market cap
USD 576M
P/E
2.8x
P/B
0.99x
ROE
46.6%
Dividend yield
5.49%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is HQL.US undervalued?

Graham number
Price18.95
Graham value54.42
Discount65.2%

HQL.US trades 65.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Tekla Life Sciences Investors fundamental analysis

No fundamental analysis for Tekla Life Sciences Investors yet.

Tekla Life Sciences Investors stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Tekla Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management…

Full company profile